Type 1 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK

Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins continue to dominate the T1D market; they are the primary treatment option for disease management. Long-acting and rapid-acting insulins are the patient-share leaders in the United States. Differences exist in the choice of branded insulin, choice of regimen, and order in which brands and/or regimens are prescribed. In addition, biosimilar insulins have added a layer of complexity to the T1D therapy market. The increasing use of insulin pumps is also playing a role in the evolving T1D market.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed T1D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T1D patients?
  • How have ultra-rapid insulins Fiasp and Lyumjev been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of T1D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of T1D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Novo Nordisk, Sanofi, Eli Lilly

Key drugs: Lyumjev, Lantus, Levemir, Toujeo, Apidra, NovoLog, Fiasp, Humalog, Admelog, Basaglar

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

Table of contents

  • Type 1 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms CDA Type 1 Diabetes US March 2022
    • Treatment Algorithms CDA Type 1 Diabetes 2022 Dashboard

Login to access report

launch Related Market Assessment Reports